CDK4/6 Inhibition in the Metastatic Setting: Where Are We Headed?

Sakach, Elizabeth; Keskinkilic, Merve; Wood, Sarah; Canning, Madison; Kalinsky, Kevin

Sakach, Elizabeth; Keskinkilic, Merve; Wood, Sarah; Canning, Madison; Kalinsky, Kevin.

Afiliación

Sakach E; Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA. esakach@emory.edu.
Keskinkilic M; Department of Medical Oncology, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey.
Wood S; Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Canning M; Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.
Kalinsky K; Winship Cancer Institute, Emory University, Atlanta, GA, 30322, USA.

Curr Treat Options Oncol ; 24(9): 1103-1119, 2023 09.

Article en En | MEDLINE | ID: mdl-37314645

Asunto(s)

Neoplasias de la Mama; Neoplasias Primarias Secundarias; Humanos; Femenino; Calidad de Vida; Oncogenes; Neoplasias de la Mama/tratamiento farmacológico; Terapia Molecular Dirigida; Receptor ErbB-2; Quinasa 4 Dependiente de la Ciclina; Quinasa 6 Dependiente de la Ciclina; Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos

Palabras clave

CDK4/6 inhibitor; Endocrine resistance, ctDNA; Hormone therapy; Metastatic breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Neoplasias Primarias Secundarias Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google